Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years

Chemotherapy Induced Nausea and Vomiting Clinical Trial

Official title:

An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 6 to 12 Years)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01596413
• Other study ID #: 392MD/46/C
• Status: Withdrawn
• Phase: Phase 1

Study information

• Verified date: March 2021
• Source: Kyowa Kirin Pharmaceutical Development Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.

Description:

This is an open-label, multi-center, cross-over study in male and female pediatric cancer patients, aged 6 to 12 years of age who are receiving at least 2 cycles of emetogenic chemotherapy requiring 5-HT3 antagonist treatment of up to 5 days duration. The study is designed to evaluate the safety and PK of transdermal granisetron (Sancuso® patch) in a pediatric population (aged 6 to 12 years), using a population PK approach.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 12 Years

Eligibility

Inclusion Criteria:

1. 6 to 12 years of age inclusive at screening.

2. Written patient or parental (or appropriate legal representative) IRB approved informed consent as appropriate.

3. Written patient assent (as appropriate).

4. Confirmed malignancy.

5. Scheduled to receive 2 or more cycles* of emetogenic chemotherapy requiring 5-HT3 antagonist treatment.

6. Scheduled to receive one or more consecutive days of 5-HT3 antagonist treatment, per cycle, as CINV prophylaxis.

• The cycles of chemotherapy must be consecutive (i.e. one followed by the other) but do not have to be the first and second cycle of a line of treatment.

Exclusion Criteria:

1. Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.

2. Clinical or laboratory signs and symptoms of significant cerebral, cardiovascular, respiratory, renal, hepatobiliary, pancreatic or infectious disease, which in the Investigator's judgment may interfere with the study assessment or completion of the study.

3. Patients with a known history or predisposition to cardiac conduction interval abnormalities, including QT Syndrome, or known family history of long QT Syndrome or taking medications that are known to prolong the QT interval.

4. Patients scheduled to have routine surgery during the study duration.

5. Patients with a life expectancy of < 6 months.

6. Scarring or significant skin disease on both upper arms.

7. Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.

8. Patients who are known or thought to be sexually active must use effective birth control.**

9. Administration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments.

10. Any conditions associated with non-compliance.

• Effective birth control includes absolute abstinence or double barrier birth control methods i.e. condom and one of the following: combined oral contraceptive, diaphragm, depot contraceptive injection.

Related Conditions & MeSH terms

• Chemotherapy Induced Nausea and Vomiting
• Vomiting

Intervention

Drug:
• Sancuso
granisetron transdermal system
• IV granisetron
IV

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Kyowa Kirin Pharmaceutical Development Ltd

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma concentration	Analysis of the plasma concentration of Intravenous granisetron vs transdermal granisetron in pediatric patients receiving chemotherapy over two sequential cycles.	Up to 7 days
Secondary	Number of participants with adverse events, application site assessment and clinically significant changes in laboratory assessments over 2 cycles of chemotherapy	Incidence, frequency, and severity of AEs and SAEs, including clinically significant changes in laboratory assessments and application site assessment.	From screening until 15 days after the last dose of IV granisetron
Secondary	Number of participants with change in physical assessment including height, weight, BMI and BSA	Change in height and weight to calculate BMI and BSA	Through study completion, an average of 8 weeks
Secondary	Number of participants with change in vital signs	Change in pulse, systolic and diastolic blood pressures measurements	Through study completion, an average of 8 weeks
Secondary	Number of participants with change in ECG parameters	12 lead ECGs will be conducted to time match PK samples after at least 5 minutes supine rest	Through study completion, an average of 8 weeks